You are here: Industry Insights > cardiovascular

News List

APO(a)-LRX Found to Reduce Lipoprotein(a) Levels drugs
January 03, 2020
For patients with elevated lipoprotein(a) levels and established cardiovascular disease, hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRX (APO(a)-LRX) reduces lipoprotein(a) levels ...
Duration of Diabetes History Tied to Higher Short-Term Mortality Risk drugs
December 26, 2019
In older adults, long-standing diabetes has a substantial and independent effect on short-term mortality, according to a study published online in Diabetes Care.
Pharmacist-Led Interventions Cut Cardiovascular Risk Factors drugs
December 26, 2019
Pharmacist-led interventions in general practice can significantly reduce medical risk factors associated with cardiovascular events ...
Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk drugs
December 26, 2019
Elevated concentrations of non-high-density lipoprotein (non-HDL) cholesterol are associated with an increased long-term risk for atherosclerotic cardiovascular disease ...
Drug approved which reduces risk of cardiovascular events europeanpharmaceuticalreview
December 18, 2019
The FDA has approved Vascepa (icosapent ethyl) as a secondary therapy to reduce cardiovascular events in adults.
Severe Adverse Cardiovascular Events Associated With Ibrutinib drugs
September 27, 2019
Cardiovascular adverse drug reactions (CV-ADR) occur in association with ibrutinib, according to a study published in the issue of the Journal of the American College of Cardiology.
Dapagliflozin Lowers Risk for Worsening Heart Failure drugs
September 24, 2019
For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes ...
Higher Fat Mass May Up Risk for Major Adverse CV Events in T2DM drugs
September 24, 2019
In patients with type 2 diabetes, higher fat mass is associated with a higher risk for major adverse cardiovascular events ...
Cardiovascular Disease Risk Underestimated in Patients With Mental Illness drugs
September 23, 2019
Cardiovascular disease (CVD) risk assessment tools that do not include severe mental illness as a predictor could be substantially underestimating CVD risk, according to a study published online in PLOS ONE.
Occasional Napping Linked to Lower Risk for Cardiovascular Events drugs
September 12, 2019
Napping once or twice per week is associated with a lower risk for incident cardiovascular disease (CVD) events, according to a study published online in Heart.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page